Clinical Scorecard: Impact of Maternal Medication Use During Pregnancy on Childhood Cancer Risk: A Comprehensive Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Childhood cancer including leukemia, lymphomas, and CNS tumors
Key Mechanisms
Multifactorial etiology involving genetic predisposition, environmental exposures, infections during pregnancy, and prenatal medication use
Target Population
Children up to 19 years old with prenatal exposure to maternal medications
Care Setting
Prenatal care and pediatric oncology
Key Highlights
Childhood cancer is the leading cause of disease-related death in children over one year of age.
Up to 90% of pregnant women use medications, but the impact on childhood cancer risk remains unclear.
This systematic review and meta-analysis consolidates evidence on prenatal medication exposure and childhood cancer risk.
Guideline-Based Recommendations
Diagnosis
Diagnose childhood cancers based on clinical presentation and confirm with appropriate pathological and imaging studies.
Consider detailed prenatal exposure history including maternal medication use during pregnancy.
Management
Manage childhood cancers according to established pediatric oncology protocols.
Counsel pregnant women on medication use considering potential but unclear risks to offspring.
Monitoring & Follow-up
Monitor children with known prenatal exposure to medications for early signs of malignancy, especially leukemia and CNS tumors.
Follow-up should be individualized based on exposure type and risk factors.
Risks
Genetic predisposition accounts for only 5-10% of childhood cancers; environmental and prenatal factors including medication exposure may contribute.
Certain infections and chemical exposures during pregnancy increase childhood cancer risk.
Diethylstilbestrol exposure is excluded due to known increased cancer risk.
Patient & Prescribing Data
Pregnant women prescribed medications including antibiotics, analgesics, antiemetics, hormones, and vitamin supplements
Medication use during pregnancy is common; however, current evidence on its association with childhood cancer risk is inconsistent and requires further investigation.
Clinical Best Practices
Obtain comprehensive medication histories during prenatal visits.
Weigh benefits and potential risks when prescribing medications to pregnant women.
Avoid medications with established carcinogenic risks to the fetus, such as diethylstilbestrol.
Promote awareness of multifactorial risk factors for childhood cancer including genetic and environmental influences.
Encourage further research and data collection on prenatal medication exposure and childhood cancer outcomes.
